株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗糖尿病薬の世界市場予測

Global Antidiabetics Pharmaceutical Market Forecast 2023

発行 NAVADHI Market Research Pvt Ltd 商品コード 869597
出版日 ページ情報 英文 316 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.60円で換算しております。
Back to Top
抗糖尿病薬の世界市場予測 Global Antidiabetics Pharmaceutical Market Forecast 2023
出版日: 2019年06月07日 ページ情報: 英文 316 Pages
概要

当レポートでは、世界の抗糖尿病薬市場について、市場構造、市場動向、市場成長の促進要因・抑制要因を含めて詳細に分析しており、癌市場関連のリスク、主な業界団体、競合情勢、および主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 イントロダクション:医薬品産業

第3章 世界の抗糖尿病薬市場のニーズ

  • 世界人口の増加 & 高齢化
  • 貧困 & 中産階級世帯の所得水準の上昇

第4章 世界の抗糖尿病薬市場の予測

  • 世界の医薬品市場:治療領域別の予測

第5章 世界の抗糖尿病薬市場における成長促進要因・抑制要因

第6章 世界の抗糖尿病薬市場に関連するリスク

  • 特許失効・知的財産保護を喪失するリスク
  • 新製品の商業的成功リスク
  • R&Dへの取り組みが失敗するリスク
  • 薬価管理のリスク
  • 新たな法規制の遵守に失敗するリスク
  • 複雑な製造工程における品質管理のリスク
  • サイバー攻撃・データ漏えいのリスク
  • 為替レート・金利変動のリスク
  • 不安定な世界政治・経済状態のリスク

第7章 世界の医薬品市場関連の業界団体

  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Association of the British Pharmaceutical Industry (ABPI)
  • 日本製薬工業協会 (JPMA)
  • Indian Drug Manufacturers' Association (IDMA)

第8章 世界の抗糖尿病薬市場における主要企業のプロファイル

  • Novo Nordisk A/S
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • AstraZeneca PLC
  • Merck KGaA
  • Merck & Co., Inc.
  • 武田医薬品工業
  • Sanofi S.A.
  • Eli Lilly and Company
  • Bayer

第9章 世界の抗糖尿病薬市場における競合情勢

  • 上位10社の競合情勢:抗糖尿病薬関連の収益
  • 上位10社の競合情勢:総収益
  • 上位10社の競合情勢:世界の医薬品収益
  • 上位10社の競合情勢:米国の医薬品収益
  • 上位10社の競合情勢:R&D支出額
  • 上位10社の競合情勢:EPS (1株当たり利益)
  • 上位10社の競合情勢:EBITDA
  • 上位10社の競合情勢:総収益予測
  • 上位10社の競合情勢:上位3製品の収益

第10章 世界の癌市場分析

  • ポーターのファイブフォース分析
  • SWOT分析

第11章 世界の癌市場における現在・将来の動向

目次
Product Code: NAV0619006

Global antidiabetics pharmaceutical market is expected to grow in near future as aging and growing population, rising income levels, and emerging medical conditions and increase of lifestyle diseases help increase the demand for diabetes treatment.

“Global antidiabetics pharmaceutical market is expected to be worth USD 56.18 billion by 2023.”

As per NAVADHI Market Research, global antidiabetics pharmaceutical market will we worth USD 56.18 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

As per Diabetes Atlas 8th edition 2017, International Diabetes Federation, there are around 425 million people in the world who are living with diabetes, with Type 2 diabetes accounting for 90 - 95 percent of all cases. This number is expected to increase to 629 million people by 2045.

This growth in antidiabetics pharmaceutical market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global antidiabetics pharmaceutical industry. Another aspect which is leading this growth is rising focus of antidiabetics pharmaceuticals companies to tap the obesity market as done by Novo Nordisk via its obesity treatment drug Saxenda®. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry which is fueling this growth. Also, no competition for generic manufacturers for insulin which is mostly controlled by Eli Lilly, Novo Nordisk and Sanofi has helped the market grow in revenue terms.

On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global antidiabetics pharmaceutical industry. In U.S. lawmakers have grilled pharma executives over higher insulin prices. This prompted Eli Lilly to introduce Lispro, a generic alternative to its insulin drug Humalog since lawmakers in their hearing had used Humalog's rising price as example during the hearing. Antidiabetics pharmaceutical companies are forced to reduce their research and development (R&D) spending and resort to huge layoffs to offset the decreasing margins on diabetes related drugs. In April 2019, Sanofi announced a new round of layoffs beginning in June 2019 to its primary care and diabetes sales teams after its insulin product sales dropped 13.8% on the year in 2018. Eli Lilly has experienced similar revenue pressure, reporting in 2018 that despite Humalog's list price growing 52% over five years, the drug's net price actually slipped 8%. It forced Eli Lilly to restructure itself in 2017 resulting in 3,500 layoffs.

Navadhi has provided detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global antidiabetics pharmaceutical market namely: Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc, Boehringer Ingelheim, AstraZeneca PLC, Johnson & Johnson, Merck KGaA, Bayer and Takeda Pharmaceutical Company Limited.

Scope of the Global Antidiabetics Pharmaceutical Market Forecast 2023 Report:

  • 1. This report provides detailed information about Global antidiabetics pharmaceutical market including future market forecasts till 2023.
  • 2. This report identifies the need for focusing on global antidiabetics pharmaceutical market.
  • 3. The report identifies the growth drivers and inhibitors for global antidiabetics pharmaceutical market.
  • 4. The report identifies various risks associated with global antidiabetics pharmaceutical market.
  • 5. This report has detailed profiles top 10 key players in Global antidiabetics pharmaceutical market covering their business strategy, financial performance, future forecasts and SWOT analysis.
  • 6. This report provides competitive landscape among top 10 key companies in Global antidiabetics pharmaceutical market.
  • 7. This report provides Porter's Five Forces analysis for Global antidiabetics pharmaceutical market.
  • 8. This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global antidiabetics pharmaceutical market.
  • 9. This report provides information about current and future trends for Global antidiabetics pharmaceutical market.

Table of Contents

1. Executive Summary

  • Scope of the Global Antidiabetics Pharmaceutical Market Forecast 2023 Report
  • Research Methodology

2. Introduction of Pharmaceuticals Industry

  • Key Product Terms Used in Pharmaceuticals Industry
  • Pharmaceuticals
  • Innovative Drugs
  • Orphan Drugs
  • Generic Drugs
  • Commodity Generic Drugs
  • Branded Generic Drugs
  • Biologics
  • Biosimilars
  • Over-the-counter(OTC) Drugs
  • Active Pharmaceutical Ingredients(APIs)
  • Excipients
  • Research and Development(R&D) Phases of Pharmaceuticals Industry
  • Industry-Wise Research and Development(R&D) Investment
  • Phase Wise Research and Development(R&D) Investment in Pharmaceuticals Industry
  • Global Pharmaceuticals Industry Value Chain Analysis

3. Need for Global Antidiabetics Market

  • Rising & Ageing Global Population
  • Increasing Income Levels of Poor & Middle-Class Families

4. Forecast for Global Antidiabetics Pharmaceutical Market 2023

  • 4.1. Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023
    • 4.1.1. Forecast for Global Antidiabetics Pharmaceutical Market 2018-2023

5. Growth Drivers and Inhibitors for Global Antidiabetics Pharmaceutical Market

6. Risks Associated with Global Antidiabetics Pharmaceutical Market

  • 6.1. Risk of Patent Expiry and Loss of Intellectual Property Protection
  • 6.2. Risk of Commercial Success of New Products
  • 6.3. Risk of Failed Research and Development Effort
  • 6.4. Risk of Drug Price Controls
  • 6.5. Risk of Failure to Comply with New Laws and Regulations
  • 6.6. Risk of Quality Control During Complex Manufacturing Process
  • 6.7. Risk of Cyber-Attacks and Data Breach
  • 6.8. Risk of Volatile Currency Exchange Rates and Interest Rates
  • 6.9. Risk of Unstable Global Political and Economic Conditions

7. Industry Associations Related to Global Pharmaceuticals Market

  • 7.1. European Federation of Pharmaceutical Industries and Associations(EFPIA)
  • 7.2. International Federation of Pharmaceutical Manufacturers & Associations(IFPMA)
  • 7.3. Pharmaceutical Research and Manufacturers of America(PhRMA)
  • 7.4. Association of the British Pharmaceutical Industry(ABPI)
  • 7.5. Japan Pharmaceutical Manufacturers Association(JPMA)
  • 7.6. Indian Drug Manufacturers' Association(IDMA)

8. Profile of Key Players in Global Antidiabetics Pharmaceutical Market

  • 8.1. Novo Nordisk A/S
    • 8.1.1. Company Profile
    • 8.1.2. Novo Nordisk A/S in Pharmaceuticals Manufacturing Value Chain
    • 8.1.3. Novo Nordisk A/S: Financial Performance
      • 8.1.3.1. Novo Nordisk A/S: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.1.3.2. Novo Nordisk A/S: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.1.3.3. Novo Nordisk A/S: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.1.4. Novo Nordisk A/S: Business Strategy
      • 8.1.4.1. Product Level Strategy
    • 8.1.5. SWOT Analysis of Novo Nordisk A/S
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.2. Boehringer Ingelheim GmbH
    • 8.2.1. Company Profile
    • 8.2.2. Boehringer Ingelheim GmbH in Global Pharmaceuticals Manufacturing Value Chain
    • 8.2.3. Boehringer Ingelheim GmbH: Financial Performance
      • 8.2.3.1. Boehringer Ingelheim GmbH: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.2.3.2. Boehringer Ingelheim GmbH: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.2.3.3. Boehringer Ingelheim GmbH: Division-Wise Revenue FY 2018(in USD billion)
    • 8.2.4. Boehringer Ingelheim: Business Strategy
      • 8.2.4.1. Product Level Strategy
    • 8.2.5. SWOT Analysis of Boehringer Ingelheim GmbH
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.3. Johnson & Johnson
    • 8.3.1. Company Profile
    • 8.3.2. Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
    • 8.3.3. Johnson & Johnson Financial Performance
      • 8.3.3.1. Johnson & Johnson: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.3.3.2. Johnson & Johnson: Division-Wise Revenue FY 2018(in USD billion)
      • 8.3.3.3. Johnson & Johnson: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.3.3.4. Johnson & Johnson: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.3.4. Johnson & Johnson: Business Strategy
      • 8.3.4.1. Product Level Business Strategy
    • 8.3.5. Johnson & Johnson's Pharmaceutical Division Growth Drivers
    • 8.3.6. SWOT Analysis of Johnson & Johnson
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.4. AstraZeneca PLC
    • 8.4.1. Company Profile
    • 8.4.2. AstraZeneca PLC in Global Pharmaceuticals Manufacturing Value Chain
    • 8.4.3. AstraZeneca PLC: Financial Performance
      • 8.4.3.1. AstraZeneca PLC: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.4.3.2. AstraZeneca PLC: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.4.3.3. AstraZeneca PLC: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.4.4. AstraZeneca PLC: Business Strategy
      • 8.4.4.1. Product Level Strategy
    • 8.4.5. SWOT Analysis of AstraZeneca Plc
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.5. Merck KGaA
    • 8.5.1. Company Profile
    • 8.5.2. Merck KGaA in Global Pharmaceuticals Manufacturing Value Chain
    • 8.5.3. Merck KGaA: Financial Performance
      • 8.5.3.1. Merck KGaA: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.5.3.2. Merck KGaA: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.5.3.3. Merck KGaA: Division-Wise Revenue FY 2018(in USD billion)
      • 8.5.3.4. Merck KGaA: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.5.4. Merck KGaA: Business Strategy
      • 8.5.4.1. Product Level Strategy
    • 8.5.5. SWOT Analysis of Merck KGaA
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.6. Merck & Co., Inc.
    • 8.6.1. Company Profile
    • 8.6.2. Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.6.3. Merck & Co., Inc.: Financial Performance
      • 8.6.3.1. Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.6.3.2. Merck & Co., Inc.: Division-Wise Revenue FY 2018(in USD billion)
      • 8.6.3.3. Merck & Co., Inc.: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.6.3.4. Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.6.4. Merck & Co., Inc.: Business Strategy
      • 8.6.4.1. Product Level Strategy
    • 8.6.5. SWOT Analysis of Merck & Co., Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.7. Takeda Pharmaceutical Company Limited
    • 8.7.1. Company Profile
    • 8.7.2. Takeda Pharmaceutical Company Limited in Pharma Manufacturing Value Chain
    • 8.7.3. Takeda Pharmaceutical Company Limited: Financial Performance
      • 8.7.3.1. Takeda Pharmaceutical Company Limited: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.7.3.2. Takeda Pharmaceutical Company Limited: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.7.3.3. Takeda Pharmaceutical Company Limited: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.7.4. Takeda Pharmaceutical Company Limited: Business Strategy
      • 8.7.4.1. Product Level Strategy
    • 8.7.5. SWOT Analysis of Takeda Pharmaceutical Company Limited
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.8. Sanofi S.A.
    • 8.8.1. Company Profile
    • 8.8.2. Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.8.3. Sanofi S.A.: Financial Performance
      • 8.8.3.1. Sanofi S.A.: Geography-Wise Revenue
    • 8.8.4. Sanofi S.A.: Business Strategy
      • 8.8.4.1. Sanofi S.A. Revenue by Global Business Units(GBU's)
      • 8.7.4.2. Sanofi S.A. Revenue by Global Franchise
    • 8.8.5. SWOT Analysis of Sanofi S.A.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 8.8.6. Sanofi's TOP 10 Blockbusters Drugs Revenue in FY 2018(in Euro millions)
  • 8.9. Eli Lilly and Company
    • 8.9.1. Company Profile
    • 8.9.2. Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
    • 8.9.3. Eli Lilly: Financial Performance
      • 8.9.3.1. Eli Lilly: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.9.3.2. Eli Lilly: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.9.3.3. Eli Lilly: Division-Wise Revenue FY 2018(in USD billion)
      • 8.9.3.4. Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018(in USD billion)
      • 8.9.3.5. Eli Lilly: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.9.4. Eli Lilly: Business Strategy
      • 8.9.4.1. Product Level Strategy
    • 8.9.5. SWOT Analysis of Eli Lilly and Company
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.10. Bayer
    • 8.10.1. Company Profile
    • 8.10.2. Bayer in Global Pharmaceuticals Manufacturing Value Chain
    • 8.10.3. Bayer: Financial Performance
      • 8.10.3.1. Bayer: Overall Revenue FY 2013-FY 2019(in Euro billion)
      • 8.10.3.2. Bayer: Division-Wise Revenue FY 2018(in Euro billion)
      • 8.10.3.3. Bayer: Geography-Wise Revenue FY 2018(in Euro billion)
      • 8.10.3.4. Bayer: Best Selling Pharmaceutical Products Revenue FY 2018(in Euro billion)
      • 8.10.3.5. Bayer: Best Selling Consumer Health Products Revenue FY 2018(in Euro billion)
      • 8.10.3.6. Bayer: Crop Science Segment-Wise Revenue FY 2018(in Euro billion)
      • 8.10.3.7. Bayer: Best Selling Animal Health Products Revenue FY 2018(in Euro billion)
    • 8.10.4. Bayer AG: Business Strategy
      • 8.10.4.1. Product Level Strategy
    • 8.10.5. SWOT Analysis of Bayer AG
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats

9. Competitive Landscape in Global Antidiabetics Pharmaceutical Market

  • 9.1. Competitive Landscape Among Top 10 Antidiabetics Companies by Antidiabetics Revenue
  • 9.2. Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue
  • 9.3. Competitive Landscape Among Top 10 Antidiabetics Companies by Global Pharmaceuticals Revenue
  • 9.4. Competitive Landscape Among Top 10 Antidiabetics Companies by United States Revenue
  • 9.5. Competitive Landscape Among Top 10 Antidiabetics Companies by Research and Development(R&D) Expenditure
  • 9.6. Competitive Landscape Among Top 10 Antidiabetics Companies by Earning Per Share(EPS)
  • 9.7. Competitive Landscape Among Top 10 Antidiabetics Companies by Earnings Before Interest, Tax, Depreciation and Amortization(EBITDA)
  • 9.8. Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue Forecast
  • 9.9. Competitive Landscape Among Top 10 Antidiabetics Companies by Top 3 Product Revenues

10. Analysis of Global Antidiabetics Pharmaceutical Market

  • 10.1. Porter's Five Forces Analysis of Global Antidiabetics Market
  • 10.2. SWOT Analysis of Global Antidiabetics Pharmaceutical Market
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats

11. Current and Future Trends in Global Antidiabetics Pharmaceutical Market

  • List of Exhibits
  • Notes
  • Company Information

List of Exhibits

  • Exhibit 2.1: Research and Development Phases of Pharmaceuticals Industry
  • Exhibit 2.2: Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
  • Exhibit 2.3: Phase-Wise Research and Development Investment in Pharmaceuticals Industry
  • Exhibit 2.4: Global Pharmaceuticals Industry Value Chain Analysis
  • Exhibit 3.1: Country-Wise Population Forecast 2016-2023 (in millions)
  • Exhibit 3.2: Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
  • Exhibit 4.1: Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
  • Exhibit 4.2: Forecast for Global Antidiabetics Pharmaceutical Market 2018-2023 (in USD billion)
  • Exhibit 5.1: Growth Drivers and Inhibitors for Global Antidiabetics Pharmaceutical Market
  • Exhibit 6.1: Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
  • Exhibit 7.1: Key Information of EFPIA
  • Exhibit 7.2: Contact details of EFPIA
  • Exhibit 7.3: List of EFPIA Members
  • Exhibit 7.4: Key Information of IFPMA
  • Exhibit 7.5: Contact details of IFPMA
  • Exhibit 7.6: List of IFPMA Members
  • Exhibit 7.7: Key Information of PhRMA
  • Exhibit 7.8: Contact details of PhRMA
  • Exhibit 7.9: List of PhRMA Members
  • Exhibit 7.10: Key information of ABPI
  • Exhibit 7.11: Contact details of ABPI
  • Exhibit 7.12: List of ABPI Members
  • Exhibit 7.13: Key Information of JPMA
  • Exhibit 7.13: Key Information of JPMA
  • Exhibit 7.15: List of JPMA Members
  • Exhibit 7.16: Key information of IDMA
  • Exhibit 7.17: Contact details of IDMA
  • Exhibit 8.1: Key Information of Novo Nordisk A/S
  • Exhibit 8.2: Contact information of Novo Nordisk A/S
  • Exhibit 8.3: Novo Nordisk A/S in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.4: Revenue of Novo Nordisk A/S FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.5: Revenue Growth of Novo Nordisk A/S FY 2014-FY 2019 (in %)
  • Exhibit 8.6: Geography-Wise Revenue of Novo Nordisk A/S in FY 2018 (in USD billion)
  • Exhibit 8.7: United States Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
  • Exhibit 8.8: United States Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
  • Exhibit 8.9: Rest of North America Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
  • Exhibit 8.10: Rest of North America Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
  • Exhibit 8.11: Europe Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
  • Exhibit 8.12: Europe Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
  • Exhibit 8.13: AAMEO (Africa, Asia, Middle East and Oceania) Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
  • Exhibit 8.14: AAMEO (Africa, Asia, Middle East and Oceania) Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
  • Exhibit 8.15: China Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
  • Exhibit 8.16: China Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
  • Exhibit 8.17: Japan and Korea Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
  • Exhibit 8.18: Japan and Korea Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
  • Exhibit 8.19: Latin America Revenue of Novo Nordisk A/S FY 2016-FY 2018 (in USD billion)
  • Exhibit 8.20: Latin America Revenue Growth of Novo Nordisk A/S FY 2017-FY 2018 (in %)
  • Exhibit 8.21: Therapy Area-Wise Revenue of Novo Nordisk A/S in FY 2018 (in USD billion)
  • Exhibit 8.22: Segment-Wise, Therapy and Geography Area-Wise Revenue of Novo Nordisk A/S FY 2018 (in USD billion)
  • Exhibit 8.23: SWOT Analysis of Novo Nordisk A/S
  • Exhibit 8.24: Key Information of Boehringer Ingelheim
  • Exhibit 8.25: Contact Information of Boehringer Ingelheim
  • Exhibit 8.26: Boehringer Ingelheim GmbH in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.27: Revenue of Boehringer Ingelheim FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.28: Revenue Growth of Boehringer Ingelheim FY 2014-FY 2019 (in %)
  • Exhibit 8.29: Geography-Wise Revenue of Boehringer Ingelheim in FY 2018 (in USD billion)
  • Exhibit 8.30: United States Revenue of Boehringer Ingelheim FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.31: United States Revenue Growth of Boehringer Ingelheim FY 2014-FY 2018 (in %)
  • Exhibit 8.32: Germany Revenue of Boehringer Ingelheim FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.33: Germany Revenue Growth of Boehringer Ingelheim FY 2014-FY 2018 (in %)
  • Exhibit 8.34: Japan Revenue of Boehringer Ingelheim FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.35: Japan Revenue Growth of Boehringer Ingelheim FY 2014-FY 2018 (in %)
  • Exhibit 8.36: Division-Wise Revenue of Boehringer Ingelheim in FY 2018 (in USD billion)
  • Exhibit 8.37: Pharmaceuticals Division Revenue of Boehringer Ingelheim FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.38: Animal Division Revenue of Boehringer Ingelheim FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.39: Biopharmaceuticals Division Revenue of Boehringer Ingelheim FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.40: Division and Therapy Area-Wise Revenue of Boehringer Ingelheim FY 2018 (in USD billion)
  • Exhibit 8.41: SWOT Analysis of Boehringer Ingelheim GmbH
  • Exhibit 8.42: Key Information of Johnson & Johnson
  • Exhibit 8.43: Contact information of Johnson & Johnson
  • Exhibit 8.44: Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.45: Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.46: Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
  • Exhibit 8.47: Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.48: Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.49: Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.50: Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.51: Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.52: Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.53: Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
  • Exhibit 8.54: SWOT Analysis of Johnson & Johnson
  • Exhibit 8.55: Key Information of AstraZeneca PLC
  • Exhibit 8.56: Contact Information of AstraZeneca PLC
  • Exhibit 8.57: AstraZeneca PLC in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.58: Revenue of AstraZeneca PLC FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.59: Revenue Growth of AstraZeneca PLC FY 2014-FY 2019 (in %)
  • Exhibit 8.60: Geography-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
  • Exhibit 8.61: United States Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.62: United States Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.63: China Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.64: China Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.65: United Kingdom Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.66: United Kingdom Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.67: France Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.68: France Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.69: Germany Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.70: Germany Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.71: Italy Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.72: Italy Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.73: Spain Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.74: Spain Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.75: Sweden Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.76: Sweden Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.77: Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.78: Rest of Europe Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.79: Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.80: Canada Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.81: Rest of Americas Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.82: Rest of Americas Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.83: Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.84: Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.85: Japan Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.86: Japan Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.87: Rest of Asia, Africa & Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.88: Rest of Asia, Africa & Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.89: Therapy Area-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
  • Exhibit 8.90: Therapy and Geography Area-Wise Revenue of AstraZeneca PLC FY 2018 (in USD billion)
  • Exhibit 8.91: SWOT Analysis of AstraZeneca PLC
  • Exhibit 8.92: Key Information of Merck KGaA
  • Exhibit 8.93: Contact Information of Merck KGaA
  • Exhibit 8.94: Merck KGaA in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.95: Revenue of Merck KGaA FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.96: Revenue Growth of Merck KGaA FY 2014-FY 2019 (in %)
  • Exhibit 8.97: Geography-Wise Revenue of Merck KGaA in FY 2018 (in USD billion)
  • Exhibit 8.98: Europe Revenue of Merck KGaA FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.99: Europe Revenue Growth of Merck KGaA FY 2014-FY 2018 (in %)
  • Exhibit 8.100: North America Revenue of Merck KGaA FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.101: North America Revenue Growth of Merck KGaA FY 2014-FY 2018 (in %)
  • Exhibit 8.102: Asia Pacific Revenue of Merck KGaA FY 2015-FY 2018 (in USD billion)
  • Exhibit 8.103: Asia Pacific Revenue Growth of Merck KGaA FY 2016-FY 2018 (in %)
  • Exhibit 8.104: Latin America Revenue of Merck KGaA FY 2015-FY 2018 (in USD billion)
  • Exhibit 8.105: Latin America Revenue Growth of Merck KGaA FY 2016-FY 2018 (in %)
  • Exhibit 8.106: Middle East and Africa Revenue of Merck KGaA FY 2015-FY 2018 (in USD billion)
  • Exhibit 8.107: Middle East and Africa Revenue Growth of Merck KGaA FY 2016-FY 2018 (in %)
  • Exhibit 8.108: Division-Wise Revenue of Merck KGaA in FY 2018 (in USD billion)
  • Exhibit 8.109: Healthcare Division Revenue of Merck KGaA FY 2015- FY 2018 (in USD billion)
  • Exhibit 8.110: Life Science Revenue of Merck KGaA FY 2015- FY 2018 (in USD billion)
  • Exhibit 8.111: Performance Materials Division Revenue of Merck KGaA FY 2015- FY 2018 (in USD billion)
  • Exhibit 8.112: Therapy Area-Wise Revenue of Merck KGaA in FY 2018 (in USD billion)
  • Exhibit 8.113: Healthcare Division Revenue of Merck KGaA FY 2018 (in USD billion)
  • Exhibit 8.114: SWOT Analysis of Merck KGaA
  • Exhibit 8.115: Key Information of Merck & Co.
  • Exhibit 8.116: Contact Information of Merck & Co.
  • Exhibit 8.117: Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.118: Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.119: Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
  • Exhibit 8.120: Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.121: Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.122: Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.123: Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.124: Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.125: Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
  • Exhibit 8.126: SWOT Analysis of Merck & Co., Inc.
  • Exhibit 8.127: Key Information of Takeda Pharmaceutical Company Limited
  • Exhibit 8.129: Takeda Pharmaceutical Company Limited in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.130: Revenue of Takeda Pharmaceutical Company Limited FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.131: Revenue Growth of Takeda Pharmaceutical Company Limited FY 2014-FY 2019 (in %)
  • Exhibit 8.132: Geography-Wise Revenue of Takeda Pharmaceutical Company Limited in FY 2018 (in USD billion)
  • Exhibit 8.133: United States Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.134: United States Revenue Growth of Takeda Pharmaceutical Company Limited FY 2017-FY 2018 (in %)
  • Exhibit 8.135: Japan Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.136: Japan Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)
  • Exhibit 8.137: Europe and Canada Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.138: Europe Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)
  • Exhibit 8.139: Russia/CIS Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.140: Russia/CIS Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)
  • Exhibit 8.141: Latin America Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.142: Latin America Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)
  • Exhibit 8.143: Asia (Excluding Japan) Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.144: Asia (Excluding Japan) Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)
  • Exhibit 8.145: Rest of World Revenue of Takeda Pharmaceutical Company Limited FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.146: Rest of World Revenue Growth of Takeda Pharmaceutical Company Limited FY 2015-FY 2018 (in %)
  • Exhibit 8.147: Therapy Area-Wise Revenue of Takeda Pharmaceutical Company Limited in FY 2018 (in USD billion)
  • Exhibit 8.148: Therapy Area-Wise Revenue of Takeda Pharmaceutical Company Limited FY 2018 (in USD billion)
  • Exhibit 8.149: SWOT Analysis of Takeda Pharmaceutical Company Limited
  • Exhibit 8.150: Key Information of Sanofi S.A.
  • Exhibit 8.151: Contact Information of Sanofi S.A.
  • Exhibit 8.152: Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.153: Sanofi S.A. Revenue FY2014-2019 (in Euro billion)
  • Exhibit 8.154: Year-wise Sanofi S.A. Growth 2014-19 (in %)
  • Exhibit 8.155: Geography-wise Sanofi S.A. Revenue Share FY 2018 (in %)
  • Exhibit 8.156: Geography-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
  • Exhibit 8.157: Global Business Units (GBU's)-wise Sanofi S.A. Revenue FY 2018 (in %)
  • Exhibit 8.158: Global Business Units (GBU's)-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
  • Exhibit 8.159: Global Franchise-wise Sanofi S.A. Revenue FY 2018 (in %)
  • Exhibit 8.160: Global Franchise-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
  • Exhibit 8.161: Sanofi S.A. Speciality Care Franchise Revenue FY 2018 (in %)
  • Exhibit 8.162: Sanofi S.A. Speciality Care Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.163: Sanofi S.A. Diabetes and Cardiovascular (DCV) Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.164: Sanofi S.A. Established Rx Products Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.165: Sanofi S.A. Consumer Healthcare (CHC) Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.166: Sanofi S.A. Generic Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.167: Sanofi S.A. Vaccines Franchise Revenue FY 2015-2018 (in Euro million)
  • Exhibit 8.168: SWOT Analysis of Sanofi S.A.
  • Exhibit 8.169: Top 10 Blockbuster Drug Revenue of Sanofi (in Euro millions)
  • Exhibit 8.170: Key information of Eli Lilly
  • Exhibit 8.171: Contact Information Eli Lilly
  • Exhibit 8.172: Eli Lilly in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.173: Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.174: Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
  • Exhibit 8.175: Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.176: United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.177: United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
  • Exhibit 8.178: Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.179: Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
  • Exhibit 8.180: Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.181: Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.182: Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.183: Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.184: United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.185: Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.186: Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.187: Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.188: Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.189: Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
  • Exhibit 8.190: SWOT Analysis of Eli Lilly and Company
  • Exhibit 8.191: Key Information of Bayer
  • Exhibit 8.192: Contact Information of Bayer
  • Exhibit 8.193: Bayer AG in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.194: Revenue of Bayer FY 2013- FY 2019 (in Euro billion)
  • Exhibit 8.195: Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
  • Exhibit 8.196: Division-Wise Revenue of Bayer in FY 2018 (in USD billion)
  • Exhibit 8.197: Pharmaceuticals Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
  • Exhibit 8.198: Consumer Health Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
  • Exhibit 8.199: Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.200: Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.201: Geography-Wise Revenue of Bayer in FY 2018 (in Euro billion)
  • Exhibit 8.202: Best Selling Pharmaceuticals Product Revenue of Bayer FY 2018 (in Euro billion)
  • Exhibit 8.203: Best Selling Consumer Health Product Revenue of Bayer FY 2018 (in Euro billion)
  • Exhibit 8.204: Crop Science Segment-Wise Revenue of Bayer FY 2018 (in Euro billion)
  • Exhibit 8.205: Best Selling Animal Health Product Revenue of Bayer FY 2018 (in Euro billion)
  • Exhibit 8.206: Bayer's Research and Development Projects (Phase II) as of January 31, 2019
  • Exhibit 8.207: Bayer's Research and Development Projects (Phase III) as of January 31, 2019
  • Exhibit 8.208: Bayer's Main Products Submitted for Approval as of January 31, 2019
  • Exhibit 8.209: SWOT Analysis of Bayer AG
  • Exhibit 9.1: Competitive Landscape Among Top 10 Antidiabetics Companies by Antidiabetics Revenue for FY2018 (in USD billion)
  • Exhibit 9.2: Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue for FY2018 (in USD billion)
  • Exhibit 9.3: Competitive Landscape Among Top 10 Antidiabetics Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
  • Exhibit 9.4: Competitive Landscape Among Top 10 Antidiabetics Companies by United States Revenue for FY2018 (in USD billion)
  • Exhibit 9.5: Competitive Landscape Among Top 10 Antidiabetics Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
  • Exhibit 9.6: Competitive Landscape Among Top 10 Antidiabetics Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
  • Exhibit 9.7: Competitive Landscape Among Top 10 Antidiabetics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
  • Exhibit 9.8: Competitive Landscape Among Top 10 Antidiabetics Companies by Overall Revenue Forecast for FY2019 (in USD billion)
  • Exhibit 9.9: Competitive Landscape Among Top 10 Antidiabetics Companies by Product-Wise Antidiabetics Revenue for FY2018 (in USD billion)
  • Exhibit 10.1: Porter's Five Forces Analysis for Global Antidiabetics Pharmaceutical Market
  • Exhibit 10.2: SWOT Analysis for Global Antidiabetics Pharmaceutical Market
Back to Top